Abstract
Chlormethine gel (also known as mechlorethamine) is a skin-directed therapy approved for daily treatment of MF-CTCL. Previous reports (including Gilmore 2020) explored alternative treatment schedules and suggested schedule changes may benefit patients. Patterns of initial treatment schedule and subsequent changes for chlormethine gel in a real-world setting among patients with MF-CTCL were investigated in an observational US registry between March 2015 and October 2018. Clinical characteristics and treatment information were collected, with patients followed for up to 2 years after baseline, defined here as chlormethine gel initiation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
